[go: up one dir, main page]

WO2007007151A3 - Use of anti-mad-cam antibody for the treatment of emphysema - Google Patents

Use of anti-mad-cam antibody for the treatment of emphysema Download PDF

Info

Publication number
WO2007007151A3
WO2007007151A3 PCT/IB2006/001870 IB2006001870W WO2007007151A3 WO 2007007151 A3 WO2007007151 A3 WO 2007007151A3 IB 2006001870 W IB2006001870 W IB 2006001870W WO 2007007151 A3 WO2007007151 A3 WO 2007007151A3
Authority
WO
WIPO (PCT)
Prior art keywords
emphysema
treatment
mad
cam antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/001870
Other languages
French (fr)
Other versions
WO2007007151A2 (en
Inventor
Gary Craig Burgess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Publication of WO2007007151A2 publication Critical patent/WO2007007151A2/en
Publication of WO2007007151A3 publication Critical patent/WO2007007151A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to the use of an anti-MAdCAM antibody for the manufacture of a medicament for the treatment of emphysema. Methods of treatment for emphysema using a therapeutically effective amount of an anti-MAdCAM antibody are also included.
PCT/IB2006/001870 2005-07-11 2006-07-03 Use of anti-mad-cam antibody for the treatment of emphysema Ceased WO2007007151A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69857705P 2005-07-11 2005-07-11
US60/698,577 2005-07-11

Publications (2)

Publication Number Publication Date
WO2007007151A2 WO2007007151A2 (en) 2007-01-18
WO2007007151A3 true WO2007007151A3 (en) 2007-05-18

Family

ID=37011975

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001870 Ceased WO2007007151A2 (en) 2005-07-11 2006-07-03 Use of anti-mad-cam antibody for the treatment of emphysema

Country Status (1)

Country Link
WO (1) WO2007007151A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45847E1 (en) 2004-01-09 2016-01-19 Pfizer Inc. Antibodies to MAdCAM

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916283C (en) 2015-01-09 2024-07-02 Pfizer MADCAM ANTAGONIST DOSING REGIMEN
JP7160491B2 (en) 2017-07-14 2022-10-25 ファイザー インコーポレイティッド Antibodies against MAdCAM
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006248A2 (en) * 1996-08-15 1998-02-19 Leukosite, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
EP1308726A1 (en) * 2001-11-05 2003-05-07 Warner-Lambert Company LLC Methods and compositions for screening modulators of integrins
WO2005067620A2 (en) * 2004-01-09 2005-07-28 Pfizer Inc. ANTIBODIES TO MAdCAM

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006248A2 (en) * 1996-08-15 1998-02-19 Leukosite, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
EP1308726A1 (en) * 2001-11-05 2003-05-07 Warner-Lambert Company LLC Methods and compositions for screening modulators of integrins
WO2005067620A2 (en) * 2004-01-09 2005-07-28 Pfizer Inc. ANTIBODIES TO MAdCAM

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAZAN-SOCHA S ET AL: "Integrins in pulmonary inflammatory diseases.", CURRENT PHARMACEUTICAL DESIGN. 2005, vol. 11, no. 7, March 2005 (2005-03-01), pages 893 - 901, XP009072999, ISSN: 1381-6128 *
LAZAR ALEXANDRU C ET AL: "Matrix-assisted laser desorption/ionization mass spectrometry for the evaluation of the C-terminal lysine distribution of a recombinant monoclonal antibody.", RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2004, vol. 18, no. 3, 2004, pages 239 - 244, XP009080137, ISSN: 0951-4198 *
LITTLE M ET AL: "Of mice and men: hybridoma and recombinant antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 8, 1 August 2000 (2000-08-01), pages 364 - 370, XP004215163, ISSN: 0167-5699 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45847E1 (en) 2004-01-09 2016-01-19 Pfizer Inc. Antibodies to MAdCAM
US9328169B2 (en) 2004-01-09 2016-05-03 Pfizer Inc. Human antibodies that bind human MAdCAM

Also Published As

Publication number Publication date
WO2007007151A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2007093627A3 (en) Biocidal composition
WO2008082613A3 (en) Factor ix moiety-polymer conjugates having a releasable linkage
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2007139871A3 (en) Methods and materials for making simvastatin and related compounds
WO2007127263A3 (en) Therapeutic uses of urolithins
WO2008139263A3 (en) Methods for slowing the progression of multiple sclerosis
WO2009124962A3 (en) Sulfonamides
WO2007106915A3 (en) Antibodies to egfl7 and methods for their use
EA201000433A1 (en) TREATMENT OF VASOMOTOR SYMPTOMS
WO2006075139A3 (en) Novel process for the preparation of substituted indoles
WO2008045391A3 (en) Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
WO2007007151A3 (en) Use of anti-mad-cam antibody for the treatment of emphysema
WO2008006363A3 (en) Treatment of t-cell carcinomas using bcl11b inhibitors
WO2007007160A3 (en) Anti-madcam antibodies to treat fever
WO2007076318A3 (en) Camphor-derived cxcr3 antagonists
WO2007007159A3 (en) Anti-madcam antibodies to treat uterine disorders
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
WO2006062901A3 (en) Silacycle compounds and methods of use thereof
UA99579C2 (en) Antibody binding to tau phosphorylated at serine 422 (ps422) for use in the treatment of a tauopathy
EP1907360A4 (en) Improved process for the manufacture of flecainide
ZA200606780B (en) Compounds for the treatment of diseases
WO2008006099A3 (en) Treatment of psychiatric disorders
AU2007907021A0 (en) Antibodies for the treatment of periodontal disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06779835

Country of ref document: EP

Kind code of ref document: A2